Elsevier

Gynecologic Oncology

Volume 51, Issue 3, December 1993, Pages 397-400
Gynecologic Oncology

Regular Article
Treatment of Advanced or Recurrent Endometrial Carcinoma with Single-Agent Carboplatin

https://doi.org/10.1006/gyno.1993.1310Get rights and content

Abstract

Cisplatin and the combination of cisplatin, doxorubicin, and cyclophosphamide have documented activity in women with advanced or recurrent endometrial adenocarcinoma. However, response duration has been short and toxicity is substantial. To determine if similar activity could be obtained with less morbidity, we prospectively treated 33 patients with 360 mg/m2 carboplatin given intravenously every 28 days. Mean patient age was 69 years (range 40-86); all had a Zubrod functional status of 2 or less. Seventeen patients had advanced primary tumors, and 16 had recurrent disease. Prior treatment included surgical resection in 29 cases, hormonal agents in 7, and radiotherapy in 22. No patient had received prior chemotherapy. Mean treatment was 5.7 cycles. Nine of 27 patients (33%) with measurable disease had objective responses, including three complete and six partial responses. Nonresponders included 10 patients with stable disease and 8 whose disease progressed while on treatment. Median time to response was 3 months. Median progression-free survival for responders and nonresponders was 5 and 4 months, respectively. At analysis, 20 patients had died of disease, 7 were alive with disease, and 6 were clinically free of disease. Disease-free patients include 1 with a complete response and 5 who began treatment without measurable disease. Median follow-up for surviving patients was 18 months (range 4-32). Treatment toxic effects were minimal and largely limited to myelosuppression; 3 patients had grade 3 thrombocytopenia, 1 had grade 3 neutropenia, and 5 had grade 3 anemia. Carboplatin has definite activity in endometrial carcinoma and offers a well-tolerated palliative therapeutic alternative.

References (0)

Cited by (73)

  • Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: A Japanese Gynecologic Oncology Group study (JGOG2041)

    2011, Annals of Oncology
    Citation Excerpt :

    Treatment of advanced or recurrent endometrial carcinoma most commonly involves chemotherapy, but the fact remains that chemotherapy for endometrial carcinoma may be no more than a palliative measure. The drugs for which efficacy has been studied in monotherapy for endometrial carcinoma include cisplatin, carboplatin, doxorubicin, epirubicin, and 5-fluorouracil, for which the reported response rates are 4%–42% [5–7], 28%–33% [8, 9], 37% [10], 26% [11], and 41% [12], respectively. Of these, it is presently considered that cisplatin and doxorubicin, which have relatively high response rates, and which have been studied extensively, are the key drugs for endometrial carcinoma.

  • Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: A Hellenic Co-operative Oncology Group (HeCOG) study

    2008, Gynecologic Oncology
    Citation Excerpt :

    For the small proportion of women who have advanced or recurrent disease, treatment with hormonal or chemotherapeutic agents, alone or in combination, can be considered [4–7]. Single agents with demonstrable objective responses in at least 20% of patients include taxanes, anthracyclines, and platinum compounds [7–15]. Also, a number of combination regimens have been explored over the last two decades, most in uncontrolled trials.

  • Systemic therapy in metastatic or recurrent endometrial cancer

    2007, Cancer Treatment Reviews
    Citation Excerpt :

    Carboplatin given at doses of 300–400 mg/m2 has been associated with RRs of 29%.76–78 Burke et al.76 prospectively treated 33 patients with advanced primary tumors or recurrent disease with 360 mg/m2 CBDCA given intravenously every 28 days. Nine of 27 patients (33%) with measurable disease had objective responses, including three complete and six partial responses.

View all citing articles on Scopus
View full text